Mackay Shields LLC’s AtriCure ATRC Stock Holding History

Mackay Shields LLC’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-21,900	Closed	-$984K	–	1424
2020 Q2	$984K	Buy	+21,900	New	+$954K	0.01%	1024

Other funds holding ATRC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mackay Shields LLC's ATRC Position: Q3 2020 in Review

Mackay Shields LLC sold out of AtriCure (ATRC) in Q3 2020, closing a stake of 21,900 shares — an estimated $984K sold.

Mackay Shields LLC first reported a position in ATRC in Q2 2020 and held it in 1 quarter. The position peaked at $984K in Q2 2020. 183 funds tracked by Wall St. Rank hold ATRC as of Q3 2020.

Mackay Shields LLC reported no remaining AtriCure position as of Q3 2020 after selling out during the quarter.
Mackay Shields LLC sold 21,900 AtriCure shares in Q3 2020, an estimated $984K.
Mackay Shields LLC first reported a position in AtriCure in Q2 2020 and held it in 1 quarter.
Mackay Shields LLC's AtriCure position peaked at $984K in Q2 2020.
183 funds tracked by Wall St. Rank held AtriCure as of Q3 2020.

Based on Mackay Shields LLC's 13F filing for Q3 2020, filed 4 Nov 2020.